Explore more publications!

Middle East News Center: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Center.

Press releases published on December 2, 2025

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer
Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
DPM Metals Announces Inferred Mineral Resource Estimates of 2.6 Million Gold Ounces and 1.9 Billion Pounds of Copper at the Rakita Camp
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
Rio Silver Acquires Second High-Potential Silver-Lead-Zinc Project in Central Peru
Amerigo’s Minera Valle Central (MVC) Receives Prestigious 2025 Circular Awards in Chile
Gilat Receives Approximately $10 Million Order for Direct Downlink Earth Observation Solution
New Crypto Mutuum Finance (MUTM) Reaches Critical Phase 6 Milestone With Less Than 5% Supply Remaining
TRX Gold Reports Q4 and Year-End 2025 Results
First Atlantic Nickel Reports Highest Awaruite (Nickel-Iron-Cobalt Alloy) DTR Grades and Recovery to Date From Expansion Drilling at Pipestone XL Nickel Alloy Project
Precore Gold Begins Brownfield Exploration Program at Flagship Arikepay Project
Goliath Reports 10 High-Grade Holes Up To 7.28 g/t Au Over 8.00 Meters Within 5.85 g/t Au Over 10.00 Meters In RIRG Dyke (417m - 427m downhole and 500m Above Valley Floor) At The 1.8 Km2 Surebet Discovery That Remains Open, Golddigger Property, Golden…
Mutuum Finance (MUTM) Nears Full Presale Allocation as Phase 6 Reaches 98% With Over 18,000 Investors
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions